液态活检技术用于检测肝癌术后复发的研究进展  

Research progress of liquid biopsy technology on postoperative recurrence of hepatocellular carcinoma

作　　者：莫慧敏 朱文钿 Mo Huimin;Zhu Wentian(The First Clinical College of Guangdong Medical University,Guangdong Zhanjiang 524000,China;Department of General Surgery,First People’s Hospital of Zhaoqing,Guangdong Medical University,Guangdong Zhaoqing 526000,China)

机构地区：[1]广东医科大学第一临床学院,广东湛江524000 [2]广东医科大学附属肇庆市第一人民医院普外科,广东肇庆526000

出　　处：《中国肝脏病杂志（电子版）》2024年第2期29-32,共4页Chinese Journal of Liver Diseases：Electronic Version

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)的治疗目前仍以根治性切除疗效最佳,但术后复发率及转移率较高,远期疗效较差。肝癌术后复发是一个复杂的过程,涉及多种因素,根据复发转移的危险因素筛选高危人群,术后及时使用靶向治疗、免疫治疗或再次行肝切除术可有效提高肝癌患者远期生存率甚至治愈。因此,研究与肝癌术后复发相关的危险因素是必要的。近年来生物医学技术在肿瘤领域的应用日趋成熟,通过液态活检技术对体内生物标志物进行检测已成为精准医疗领域的热点。本文就近年来通过液态活检在预测肝细胞癌术后复发相关生物标记物方面的研究进行综述。Currently,radical hepatectomy is still the most effective treatment for hepatocellular carcinoma(HCC),however,the postoperative recurrence and metastasis rates are high,and the long-term efficacy is poor.Postoperative recurrence of liver cancer is a complex process involving multiple factors.Screening high-risk populations based on risk factors for recurrence and metastasis,timely use of targeted therapy,immunotherapy,or repeat liver resection after surgery can effectively improve the long-term survival rate and even cure liver cancer.Therefore,it is necessary to research the risk factors associated with postoperative recurrence of liver cancer.In recent years,the application of biomedical technology in the field of cancer has become increasingly mature,and the detection of in vivo biomarkers through liquid biopsy technology has become a hot topic in the field of precision medicine.This paper reviewed the recent research on biomarkers related to predicting postoperative recurrence of liver cancer through liquid biopsy.

关 键 词：液态活检 肝细胞癌 肝癌术后 复发预测 

分 类 号：R735.7[医药卫生—肿瘤]